Sign up for Breaking News Email Alerts

Different regions of the brain and spinal cord house different, specialized cells. Neuralstem’s technology enables the isolation and expansion of human neural stem cells from each of these regions of the developing central nervous system (CNS) in virtually unlimited numbers from a single donated tissue. More

Neuralstem’s technology uniquely enables the creation of stable neural stem cell lines from the human hippocampus, a part of the brain involved in memory and the generation of new neurons. From these cell lines, the company can create practically unlimited amounts of hippocampal neural stem cells. More

    • NSI-566/ALS Data Shows Six Patients Improved, Stable or With Very Slow Disease Progression 700+ Days Post-surgery 5.20.13

      Updated Phase I data centered on two common clinical characteristics: earlier-stage patients with no bulbar features of ALS. Dr. Feldman presented updated data at Neuro Diabetes Medical Symposium in Romania. More

    • SiriusXM’s Doctor Radio Feature Interview 5.09.13

      Dr. Eva Feldman and ALS patient Ted Harada discuss Neuralstem’s NSI-566/ALS trials and draw listener questions from around the country during one-hour segment on SiriusXM’s Doctor Radio. More

    • NSI-566/ALS Phase I Final Data Presented 4.29.13

      Neuralstem’s method of intraspinal cell delivery found to be safe, well-tolerated, and promising for other spinal cord conditions. Data presented at American Assn. of Neurological Surgeons Annual Meeting. More

    • FDA Approves NSI-189/MDD Phase Ib Final Cohort 4.22.13

      First-in-class neurogenic small molecule compound advances in escalating dosage major depression trial, scheduled to conclude in the third quarter. More

    • BIO International Panel to Explore Traumatic Brain Injury 4.18.13

      President and CEO, Richard Garr, to focus on neurogenic NSI-189 and its potential for treatment of TBI in BIO Maryland panel, introduced by the state’s Lt. Governor, at upcoming convention. More

    • FDA Approves NSI-566/ALS Phase II Trial 4.17.13

      Dosing increases up to a maximum of 40 injections and 400,000 neural stem cells per injection; trial expands to two centers – Emory University Hospital and University of Michigan. More

    • ALS-specific Patent Added to IP Portfolio in Advance of Expected Phase II Study 4.5.13

      Notice of allowance for patent application 12/404,841 covers methods using NSI-566 cells specifically in the treatment of ALS. More

    • Neuralstem Grants Cedars-Sinai Medical Center Licenses for Academic Research 2.20.13

      Second set of licenses granted for proprietary intraspinal cell therapy surgical devices and method, used in Phase I ALS trial, enabling new era of research and treatment of spinal cord conditions and diseases. More

    • FDA Approves NSI-566/Spinal Cord Injury Trial 1.14.13

      One-year Phase I trial goal, brings same procedure and cells used in ALS trial to eight patients with T2-T12 paralysis. Cells expected to “bridge the gap,” as seen in Sept. scientific journal CELL study where rats regained movement in all lower extremity joints. More

    • Long-term NSI-566 cell survival confirmed; NIH majority funding secured for ALS Phase II 12.10.12

      Principal site investigator at Emory, Jonathan Glass, MD, presents new Phase I data at Int’l Symposium on ALS/MND in Chicago. More

    • Significant Recovery of Motor and Neurological Functions In NSI-566/
      Ischemic Stroke Rat Study 10.15.12

      Proof-of-principle data of two independent ischemic stroke animal studies, presented at Neuroscience 2012, gives strong evidence that “NSI-566 cells are ready to go into humans to treat paralysis in stroke patients.” More

    • Neuralstem Phase I/II Ischemic Stroke Trial in China Approved 9.27.12

      First-in-human direct injections into brain of
      NSI-566, same Neuralstem cell product injected into gray matter of spinal cord in recently completed FDA- approved ALS Phase I trial. More

    • “Paralyzed Rats Walk Again After Stem Cell Transplant” 9.13.12

      MIT’s Technology Review reports on CELL SCI animal research, includes connection to same NSI-566 cells as ALS trial and suggestion of hope for treatment for patients even with completely severed spinal cords. More